Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
33.40
-0.07 (-0.21%)
At close: Dec 19, 2025, 4:00 PM EST
33.37
-0.03 (-0.09%)
After-hours: Dec 19, 2025, 6:13 PM EST
Spyre Therapeutics Employees
Spyre Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 35 or 116.67% compared to the previous year.
Employees
65
Change (1Y)
35
Growth (1Y)
116.67%
Revenue / Employee
n/a
Profits / Employee
-$1,821,246
Market Cap
2.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Dec 31, 2021 | 101 | 11 | 12.22% |
| Dec 31, 2020 | 90 | 14 | 18.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SYRE News
- 14 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 6 weeks ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 2 months ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire